In summary, MSI2 accelerates the development and progression of pancreatic cancer through a novel ISYNA1‐p21/ZEB‐1 pathway, which supplies a novel gene targets in the PC treatment. The gene discussed is ZEB1; the disease is pachyonychia congenita.